GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
TPP, Trade Negotiations and Protection of Biological Product Exclusivity
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Taxation/Internal Revenue Code TAX
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit H.R.942, American Research and Competitiveness Act S. 1577 Greater Research Opportunities with Tax Help Act H.R. 8, American Taxpayer Relief Act of 2012
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Health Issues HCR
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain Security AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases H.R. 2674, 340B Program Improvement Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Medicare/Medicaid MMM
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues H. Con. Res. 112, Budget Resolution H.R. 6684, Spending Reduction Act of 2012 H.R. 8, American Taxpayer Relief Act Delay of Oral-Only Drugs in the ESRD bundle
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Budget/Appropriations BUD
FY 2013 Budget H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013 H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act H.J. Res. 117, Continuing Appropriations Resolution, 2013
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Pharmacy PHA
Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposals Report on Innovation/FDA by President's Council of Advisors on Science and Technology (PCAST) H.R. 6433, FDA User Fee Corrections Act H.R. 1513, S. 810, Great Ape Protection & Cost Savings Act of 2011
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | — |
| KATHLEEN HOLCOMBE | — |
| MARY MCGRANE | — |
Affiliated organisations
| Organisation | Location |
|---|---|
| GENZYME CORPORATION | Washington, DC, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.